Vera Therapeutics looks well placed for full approval of Trutakna (atacicept-vymj) in primary IgA nephropathy (IgAN) after ...
Vera Therapeutics Inc. VERA shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility ...
Vera Therapeutics (VERA) stock jumped 4% after two-year ORIGIN3 trial data showed Trutakna slowed kidney decline to normal ...
Asianet Newsable on MSN
VERA stock jumps 16% premarket – Trutakna cuts kidney disease progression risk by 76%, full FDA filing planned in Q4
Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.
Vera Therapeutics (VERA) stock jumps as the firm posts a late-stage trial win for its lead asset Trutakna in primary IgA ...
Investor's Business Daily on MSN
Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?
Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex ...
Additionally, valuation reality has stepped into focus: as a commercial-stage biotech scaling up operations, VERA reports ...
Add Yahoo as a preferred source to see more of our stories on Google. The season, which is just two episodes long, will once again be led by Brenda Blethyn as DCI Vera Stanhope. David Leon is also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results